Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic ActivityGenetic Engineering News. 2024 44:5, 48-50


View
Recommended Publications
Latest Publications
The state of the art in secondary pharmacology and its impact on the safety of new medicines

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions

Derek J. Leishman, Jessica Brimecombe, William Crumb, Simon Hebeisen, Steve Jenkinson, Peter J. Kilfoil, Hiroshi Matsukawa, Karim Melliti, Yusheng Qu, Journal of Pharmacological and Toxicological Methods, Volume 128, 2024, 107524, ISSN 1056-8719. DOI: 10.1007/978-3-031-52197-3

Copyright prevents linking to the article.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram